Navigation Links
Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
Date:1/7/2014

TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency (EMA). In Europe, Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrence of symptomatic venous thromboembolism (VTE). If approved, edoxaban will be authorized for marketing in all European member states.

The MAA submission is based on data from an extensive global clinical trial program that compared treatment with once-daily edoxaban to warfarin, a current standard of care for patients with atrial fibrillation (AF) or VTE. The two clinical trials that formed the basis of the submission, ENGAGE AF-TIMI 48 and Hokusai-VTE, are the largest comparative trials of a novel oral anticoagulant in these patient populations, involving 21,105 and 8,292 patients, respectively.1,2

"The submission of our MAA in Europe for edoxaban represents our long standing commitment to addressing the needs of patients living with cardiovascular diseases, including AF or VTE," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of Research and Development, Daiichi Sankyo Co., Ltd. and President and CEO of Daiichi Sankyo, Inc. in the United States. "This milestone brings us one step closer to providing a new treatment option to patients living with AF or VTE, and we look forward to working with the EMA as it conducts its review of edoxaban."

Edoxaban is currently
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
2. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
3. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
4. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
5. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
6. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
7. Orexigen Resubmits Contrave New Drug Application
8. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
9. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
10. Omeros Submits New Drug Application to U.S. FDA for OMS302
11. Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... WASHINGTON , July 24, 2014  The ... Brightree is supporting its mission to help address ... new and exclusive agreement to be the information ... service. As the leading provider of billing and ... brings unmatched HME industry expertise to support this ...
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % to Rs. 1848.46 ... India Business grew by 20.87% to Rs. 3,971.59 Mn ... Rest of World (ROW) Business grew by 20.67% to Rs. 2,113.09 ... 977.26 Mn Latin America Business grew by 33.92% to ... the research-led global integrated pharmaceutical company, today announced its results for ...
(Date:7/24/2014)... -- "North America Orthopedic Braces and Supports Market Outlook ... America Orthopedic Braces and Supports market. The report provides ... units) and average price data (in US dollars), within ... , Ankle Braces and Supports , Spinal ... Supports. Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
Breaking Medicine Technology:Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
... ANGLETON, Texas, June 2, 2011 Benchmark Electronics, Inc. ... manufacturing provider, announced today that a product it helped ... Design Excellence Award and 2011 Edison Award for best ... 3M™ Integrated Cycler, which has won a 2011 Medical ...
... 2, 2011 Craneware, Inc., the market leader ... multi-year agreement today with Kingman Regional Medical Center, ... Recognized as one of the nation,s five star ... will add Craneware InSight Denials® to the range ...
Cached Medicine Technology:Benchmark Electronics Recognized as Supplier for 2011 Design Medical Excellence Award Winner 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 3Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 4
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... a renowned wedding dress manufacturer and retailer, has recently ... . According to the company’s marketing specialist, all these ... prices, up to 59% off. The special offer will ... Most of the casual party dresses provided by iFitDress.com ... for special designs, delicate craftsmanship and affordable rates. Now, ...
(Date:7/24/2014)... [Brown University] The U.S. Preventive Services Task ... for people at high risk for cancer, but ... patients will have positive results on the screening ... testing. Many policymakers have expressed concern that this ... needlessly upset. A new study of National Lung ...
(Date:7/24/2014)... The Traffic and Leads Training Academy ... help users generate traffic and leads has just been ... throughout the internet marketing community. The excitement surrounding the ... Hendricks prompting a comprehensive review of the course. ... marketing will tell you, it can be quite challenging ...
(Date:7/24/2014)... Triangle Park, NC (PRWEB) July 24, 2014 ... elderly, ethnic minorities, and low-income households are disproportionately ... and public food safety net in the United ... International. , Under Section 743 of the Consolidated ... U.S. Department of Agriculture's Food and Nutrition Service ...
Breaking Medicine News(10 mins):Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Traffic And Leads Training Academy - Review Examining Jeff Johnson’s New IM Course Released 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3
... Accompanies Manuscript in March IssueTAMPA, Fla., March 2 ... peginterferon alfa-2a and ribavirin in patients with chronic ... was published in the March issue of ... Gastroenterological Association Institute (AGA Institute). The study showed ...
... 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that the Company has amended the maturity ... with Valens U.S. (formerly Laurus Master Funds). , ... to a near-term extension of this facility, originally ...
... 2 Cardiac Science Corporation (Nasdaq: CSCX ... rehabilitation, and informatics products, announced today that it will ... March 12, 2009 after the market close. The Company ... for 4:30 p.m. Eastern Time. During the call, ...
... APA,s Psychologically Healthy Workplace Awards, Ten Honored for ... of the economy can be felt across all ... during tough economic times reap rewards for employer ... (APA) at its Psychologically Healthy Workplace Awards ceremony ...
... uninsured and underinsured is destabilizing state,s health care safety net. Health ... , ... Detroit, Michigan (PRWEB) March 2, 2009 -- ... and destabilizing the state,s health care delivery system. More than one ...
... Drinking one glass of wine a day may lower ... a new study by the Kaiser Permanente Division of Research ... is a precursor to esophageal cancer, the nation,s fastest growing ... the last 30 years. , Barrett,s Esophagus affects 5 ...
Cached Medicine News:Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 2Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 3Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 4Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 2Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 3Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 4Health News:Drinking wine lowers risk of Barrett's esophagus, precursor to nation's fastest growing cancer 2Health News:Drinking wine lowers risk of Barrett's esophagus, precursor to nation's fastest growing cancer 3
... Cool Line catheter is inserted into the ... the superior vena cava. The Cool ... have sterile, temperature-controlled saline flowing within a ... the central circulation. The Cool Line ...
...
... ability of interventional cardiologists and cardiothoracic ... and provides non-interventional cardiologists with a ... of patients who have become refractory ... a noninvasive, atraumatic treatment for coronary ...
Our smallest port is available with either a COOK Peel-Away or COOK Micropuncture Introducer Set....
Medicine Products: